| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-09-30 | Nabriva Therapeutics (Austria) | $ 92.5 million | IPO | Infectious diseases | IPO | |
| 2015-09-29 | Asceneuron (Switzerland) | CHF 30 million (€ 27.4 million) | series A financing round | Sofinnova Partners (France) SR One (UK) Kurma Partners (France) Johnson & Johnson Innovation – JJDC (USA - NJ) MS Ventures (Germany) | Neurodegenerative diseases | Series A financing round |
| 2015-09-29 | Oncobiologics (USA - NJ) | $44 million | financing round | Sabby Management (USA - NJ) Perceptive Advisors (USA - NY) Cormorant Global Healthcare Master Fund (USA - MA) Longwood Capital Partners (USA - CA) Venbio Select Fund (USA - CA) | Financing round | |
| 2015-09-29 | Corvus Pharmaceuticals (USA - CA) | $75 million (€ 66.8 million) | series B financing round | Rock Springs Capital Management (USA - MD) Fidelity Management and Research Company (USA - MA) Blackrock (USA) accounts managed by T. Rowe Price, Jennison Associates (USA - NY) Roche Venture Fund (Switzerland) Cormorant Asset Management (USA - MA) Sphera Funds Management (Israel) venBio (USA - CA), Cowen Private Investments (USA - NY) OrbiMed (USA - NY) Adams Street Partners (USA) Novo Ventures (Denmark) | Cancer - Oncology | Series B financing round |
| 2015-09-29 | Apitope (UK) | €12 million | series B financing round | Wales Life Sciences Fund (UK) Vesalius Biocapital (Luxembourg) LRM (Belgium) PMV (Belgium) Wyvern (UK) | Autoimmune diseases - Rare diseases - Hematological diseases - Genetic diseases | Series B financing round |
| 2015-09-28 | IntraCellular Therapies (USA - NY) | $345 million | private placement | Mental diseases - Neurodegenerative diseases | Private placement | |
| 2015-09-28 | Heptares Therapeutics (UK), a wholly-owned subsidiary of Sosei Group (Japan) | $5.5 million | grant | National Institute on Drug Abuse (NIDA) (USA) | CNS diseases | Grant |
| 2015-09-22 | RegenXBio (USA - MD) | $159.4 million | IPO | Rare diseases - Genetic diseases | IPO | |
| 2015-09-21 | Inovio Pharmaceuticals (USA - PA) MedImmune (USA - global biologics arm of AstraZeneca (UK) GeneOne Life Sciences (Republic of Korea) | $45 million | grant | Defense Advanced Research Projects Agency (DARPA) (USA) | Infectious diseases | Grant |
| 2015-09-15 | UM Cure 2020 project including Curie Institute (France), Academisch Ziekenhuis Leiden (The Netherlands), Universiteit Leiden (The Netherlands), The University of Liverpool (UK), The University of Manchester (UK), Uniwersytet Jagiellonski (Poland), Karlsruher institut fuer technologie (Germany), Fundacao D. Anna Sommer Champalimaud E DR. Carlos Montez Champalimaud (Portugal), Melanoma Patient Network Europe (Sweden),Pamgene International (The Netherlands), Pep Therapy (France), Seeding Science (France) | € 6 million | grant | European Commission’s Horizon 2020 programme | Cancer - Oncology - Rare diseases | Grant |
| 2015-09-14 | Seattle Genetics (USA - WA), a wholly owned subsidiary of Takeda Pharmaceutical (Japan) | $552 million | private placement | Private placement | ||
| 2015-09-14 | Alzheimer’s Research UK (UK) MRC Technology (UK) Eisai (Japan) Eli Lilly (USA - IN) International Centre for Genetic Engineering and Biotechnology (ICGEB) (Italy) | £305,000 | grant | Dementia Consortium (UK) | Rare diseases - Neurodegenerative diseases | Grant |
| 2015-09-10 | Medicinova (USA - CA) | $17.5 million | private placement | Rare diseases - Liver diseases - Hepatic diseases | Private placement | |
| 2015-09-10 | Novadip Biosciences (Belgium) | €28 milllion | series A financing round | New Science Ventures (USA) VIVES Louvain Technology Fund (Belgium) NivelInvest (Belgium) Fund+ (Belgium) Integrale S (Belgium) RIW (Belgium) SFPI-FPIM (Belgium) Epimède (Belgium) individual investors. | Regenerative Medicine | Series A financing round |
| 2015-09-10 | Tyromab consortium | € 1.57 million | subvention | FUI (Fond Unique Interministériel - a French program supporting collaborative research projects)(France) | Cancer - Oncology | Subvention |
| 2015-09-09 | Biom’Up (France) | €31,3 million | series C financing round | Gimv (Belgium) Bpifrance Large Venture (France) Lundbeckfond Ventures (Denmark) InnoBio (France) Sham Innovation Santé (France) ACG Management (France) Sofimac (France) Mérieux Développement (France) OTC AM (France) Euroainvest (France) l’Améliane (France) company’s management team | Medical devices | Series C financing round |
| 2015-09-08 | Avexis (USA - IL) | $65 Million | series D financing round | T. Rowe Price Associates (USA - MD) Deerfield Management (USA - NY) Roche Venture Fund (Switzerland) Venrock (USA - CA) Janus Capital Management (USA) Adage Capital Management (USA - MA) RA Capital Management (USA - MA) QVT Financial (USA - NY) Rock Springs Capital Management (USA - MD) Foresite Capital Management (USA - CA) RTW Investments (USA - NY) Boxer Capital of Tavistock Life Sciences (Bahamas) | Rare diseases - Genetic diseases | Series D financing round |
| 2015-09-08 | ReViral (UK) | $ 21 million | Edmond de Rothschild Investment Partners (France) OrbiMed (USA - NY) Brace Pharma (USA - MD) | Infectious diseases | Series A financing round | |
| 2015-09-07 | iABC (inhaled Antibiotics in Bronchiectasis and Cystic fibrosis) consortium including Queen\'s University Belfast (UK), Belfast Health and Social Care Trust (UK) University Medical Center Utrecht (The Netherlands) Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung (Germany) Rijksuniversiteit Groningen (The Netherlands) Servicio Madrileño de Salud (Spain) Universitair Ziekenhuis Antwerpen (Belgium) University of Dundee (UK) Institut National de la Santé et de la Recherche, Poitiers (France) Università degli Studi di Milano (Italy) Hospices Civils de Lyon (France) Medizinische Hochschule Hannover (Germany) Universiteit Antwerpen (Belgium) University of Edinburgh (UK) Royal Brompton and Harefield NHS Foundation Trust (UK) Fundació Clínic per a la Recerca Biomèdica, Barcelona (Spain) Papworth Hospital NHS Foundation Trust (UK) Erasmus Medical Center (The Netherlands) Basilea Pharmaceutica (Switzerland) Novartis (Switzerland) | €50 million | grant | Innovative Medicines Initiative (IMI) (EU) | Rare diseases - Genetic diseases - Infectious diseases | Grant |
| 2015-09-02 | ADC Therapeutics (Switzerland) | $80 million (€70.8 milion) | private placement | Auven Therapeutics (Switzerland) AstraZeneca (UK) undisclosed leading European and US-based investors | Cancer - Oncology | Private placement |
